← Back to Search
Insulin Administration Via Liposomes
R. S. Spangler
Published 1990 · Medicine
Download PDFAnalyze on Scholarcy
Liposomes have been used in insulin therapy as a means to selectively target insulin to the liver, enhance oral absorption of insulin, and prolong insulin action. Liposomes are an effective means of delivering insulin specifically to hepatocytes. The usefulness of hepatically targeted liposomes in the treatment of diabetes is restricted due to the requirement that they be given intravenously, the dilute concentration of insulin present in liposomal preparations, and the cost associated with liposome production. Encapsulating insulin in liposomes results in enhanced oral absorption of insulin. The high doses of liposome-entrapped insulin required perorally, coupled with extreme variability in the glycemic response to peroral liposomes, limits the value of peroral liposomal insulin as a viable diabetic therapy. Insulin action can be sustained via encapsulation of insulin in liposomes given subcutaneously. Most insulin appears to remain at the injection site, and the presence of a lipid matrix for subcutaneous insulin delivery raises concerns over enhanced antigenicity of liposomal insulin given subcutaneously. Viewed in the light of the limitations outlined above, the contribution of liposomal insulin to understanding and treatment of diabetes mellitus will probably be via use of hepatically targeted liposomes as a pharmacological probe to decipher the role of the liver in the metabolic complications associated with diabetes mellitus.
This paper references
KGMM: Comparison of the effects of portal and peripheral infusions of insulin on glucose turnover and recycling in diabetic dogs
RW Stevenson (1980)
HYPOGLYCÆMIC EFFECT OF LIPOSOME-ENTRAPPED INSULIN ADMINISTERED INTRAGASTRICALLY INTO RATS
G. Dapergolas (1976)
Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.
R. DeFronzo (1985)
in normal and diabetic man
JS Wall (1980)
Metabolic responses to intraduodenal glucose loading in insulin-infused diabetic dogs.
R. W. Stevenson (1983)
Insulin as a mediator of hepatic glucose uptake in the conscious dog.
A. Cherrington (1982)
Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs.
H. M. Patel (1982)
Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man
R. DeFronzo (1983)
The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man.
E. Ferrannini (1980)
Subcutaneous administration of insulin in liposomes to diabetic dogs: persistence of action for many hours after absorption
R W Stevenson (1980)
Howard MM: Es- 26. timation of hepatic blood flow with indocyanine green
CM Leevy (1962)
Effect of charge on hepatic specific nature of vesicle encapsulated insulin in conscious dogs.
R. S. Spangler (1986)
Effect of peripheral versus portal venous administration of insulin on postprandial hyperglycemia and glucose turnover in alloxan-diabetic dogs.
R. Rizza (1981)
Comparative properties and methods of preparation of lipid vesicles (liposomes).
F. Szoka (1980)
Ketone body turnover and net hepatic ketone production in fasted and diabetic dogs.
U. Keller (1978)
DeMark BR: The deter- 24. mination of total and encapsulated insulin in vesicle formulation
MS McCracken (1986)
Critical factors in hepatic-specific delivery of insulin via liposomes
RS Spangler (1988)
The deter - 24 . mination of total and encapsulated insulin in vesicle formulation
MS McCracken (1986)
Comparison of the effects of portal and peripheral infusions of insulin on glucose turnover and recycling in diabetic dogs
RW Stevenson (1980)
High-performance liquid chromatographic determination of lipids in vesicles.
M. S. McCracken (1985)
Albisser AM: Blood glucose control and insulin clearance in unrestrained dogs portally infused with a portable insulin delivery system
Y Goriya (1980)
Effect of intraportal and peripheral insulin on glucose turnover and recycling in diabetic dogs.
R. W. Stevenson (1983)
High performance liquid chro - 23
MS McCracken (1985)
Oral administration of insulin by encapsulation within liposomes
H. M. Patel (1976)
Effect of insulin on utilization and production of circulating glucose.
J. Wall (1957)
Blood glucose control and insulin clearance in unrestrained diabetic dogs portally infused with a portable insulin delivery system
Y. Goriya (2004)
Responses to mixed meals in pancreatectomized dogs deprived of postprandial insulin.
Y. Goriya (1982)
Selective insulinization of liver in conscious diabetic dogs.
R. S. Spangler (1985)
Critical factors in hepatic - specific delivery of insulin via liposomes
MS McCracken (1988)
Comparison of the metabolic responses to portal and peripheral infusions of insulin in diabetic dogs.
R. W. Stevenson (1981)
Estimation of hepatic blood flow with indocyanine green.
C. Leevy (1962)
This paper is referenced by
Oral delivery of microencapsulated proteins.
M. D. DiBiase (1997)
INSIGHT ON SOLID LIPID NANOPARTICLES: CHARACTERIZATION AND APPLICATION IN DIABETES MELLITUS
S. Kaliamurthi (2016)
Hepatic-Directed Vesicle Insulin: A Review of Formulation Development and Preclinical Evaluation
W. Geho (2009)
Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats
M. J. Ansari (2016)
Formulation development for a zidovudine chemical delivery system 2. Towards oral and non-parenteral dosage forms
S. Amselem (1995)
Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities.
G. Russell-Jones (2011)
DEVELOPMENT AND CHALLENGES FACING FOR INSULIN ORAL DELIVERY
Venkatachalam Senthil (2013)
Studio di sistemi supramolecolari per il delivery di proteine terapeutiche
Sara Bersani (2008)
Non invasive insulins: advanced insulin therapy over this decade
T. Rajeswari (2011)
PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
L. M. Kaminskas (2009)
Insulin-eukaryotic model membrane interaction: Mechanistic insight of insulin fibrillation and membrane disruption.
B. N. Ratha (2018)
A study of the factors which may influence the isolation of porcine islets of Langerhans
S. A. White (1997)
Development of glucose-triggered pH-sensitive liposomes for a potential insulin delivery
Kim Chong-Kook (1994)
Comparison in the Glucose Response of Flexible Liposomes Loaded with Insulin with the Addition of Different Surfactants in an Experimental Diabetes Model
Sara Melisa Arciniegas (2020)
Future Developments in Insulin Delivery Systems
C. Saudek (1993)
Drug Carrier Systems for Anticancer Agents
Hiroyuki Koide (2019)
Peroral insulin delivery : new concepts and excipients
A. Sadeghi (2008)
In Vitro and In Vivo Profiles and Characterization of Insulin Nanocarriers Based in Flexible Liposomes Designed for Oral Administration
Sara Melisa Arciniegas Ruiz (2019)
30 Upcoming and New Insulin Delivery Systems
Recent Developments in Insulin Delivery Techniques
F. Kennedy (2012)
Nanoparticles: Emerging carriers for drug delivery.
S. R. Mudshinge (2011)
Insulin as an oral drug delivery: A novel approach
A. Takale (2017)
Peroral peptide delivery and absorption challenges using novel drug delivery systems: current status
Chapter 10 Oral Delivery of Microencapsulated Proteins
Mary D. DiBiase andEric M. Morrel ()
Process for Physicochemical Improvement of Ultra-flexible Liposomes Loaded with Insulin
S. Arciniegas (2019)
Insulin formulation and delivery.
J. Brange (1997)
Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats.
M. Ramadas (2000)
Fluorescence anisotropy and light-scattering studies of the interaction of insulin with liposomes
L. Šikurová (2004)
Targeted inhibition of Amyloidogenesis using a non-toxic, serum stable strategically designed cyclic peptide with therapeutic implications.
Ranit Pariary (2020)
Anticancer Agents: Drug Carrier Systems
Hiroyuki Koide (2015)
A biospecific polymeric carrier for polypeptide drugs
L. I. Valuev (2004)
Diabetes Mellitus : Implications for Physical Therapy Pharmacologic Management of Hyperglycemia in
E. Betts (2006)See more